 Tricida, Inc., a South San Francisco, CA-based Phase 3 stage biopharmaceutical company focused on the discovery and development of non-absorbed oral drug therapies, closed a 57.5m Series D financing. Wellington Management Company LLP, Venrock Healthcare Capital Partners and Cormorant Asset Management joined existing investors OrbiMed, Longitude Capital, Sibling Capital Ventures, Limulus Venture Partners and Vivo ... 